Heart Metabolics begins Phase IIb trial of perhexiline to treat HCM
Irish biopharmaceutical company Heart Metabolics has begun its Phase IIb trial of perhexiline to treat hypertrophic cardiomyopathy (HCM) and moderate-to-severe heart failure with preserved left ventricular function.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiomyopathy | Heart | Heart Failure | Hypertrophic Cardiomyopathy | Pharmaceuticals